Sanara MedTech Q2 Revenue Misses Estimates, Posts Net Loss Amid Acquisition Costs
SMTI has more than doubled off its 52-week low of $16.047 on elevated volume (2.4× avg).
Summary
Sanara MedTech reported Q2 revenue of $28.1M, up 9% year-over-year but below the $28.95M consensus. The company swung to a net loss from continuing operations, driven by higher SG&A, interest expenses, and legal/advisory costs tied to the pending MiMedx acquisition. This follows the July 29 announcement of the $35/share buyout, which sets a ceiling on standalone valuation. The earnings miss and loss highlight operational strain even as the deal progresses. The OsStic bone void filler is now expected to launch in Q1 2027, a timeline that may be irrelevant if the acquisition closes first.
At the time of this announcement, SMTI was trading at $34.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $316.1M. The 52-week trading range was $16.05 to $35.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.